{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:12:51Z","timestamp":1790118771151,"version":"4.0.1"},"reference-count":82,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The reference to vitiligo-like lesions (VLLs) induced by immune checkpoint inhibitors (ICIs) as a valuable predictive marker of treatment success of immunotherapy with ICIs in melanoma has been mentioned in the literature. Its role in non-small cell lung cancer (NSCLC)-treated patients remains a poorly recognized phenomenon with uncertain significance regarding its predictive value. A retrospective, observational, single-center report was performed, with descriptive analysis of clinicopathological and treatment characteristics of patients with stage IV NSCLC who developed ICI-induced VLL between January 2018 and December 2022, contextualized in a comprehensive review of the literature and reported cases regarding this phenomenon. During the first 5 years\u2019 experience of ICI use in stage IV NSCLC treatment, three cases of ICI-induced VLLs were diagnosed. In line with the previous reports, two of the three presented cases exhibited treatment response and favorable prognosis. The recognition and understanding of the pathophysiological processes underlying ICI-induced VLLs may represent a promising opportunity to identify a predictive marker of tumor response to ICIs, with impact in treatment selection and patient management. It also may contribute to the recognition of new patterns of molecular expression that could lead to improvements in therapeutic development.<\/jats:p>","DOI":"10.3390\/curroncol31020083","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:43:48Z","timestamp":1708505028000},"page":"1113-1128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4195-9352","authenticated-orcid":false,"given":"Jo\u00e3o Queir\u00f3s","family":"Coelho","sequence":"first","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1062-7387","authenticated-orcid":false,"given":"Raquel","family":"Rom\u00e3o","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1125-2871","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Sousa","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3066-2094","authenticated-orcid":false,"given":"S\u00e9rgio Xavier","family":"Azevedo","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6045-7059","authenticated-orcid":false,"given":"Paula","family":"Fidalgo","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-3584","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"},{"name":"Oncology Research Unit, 4050-346 Porto, Portugal"},{"name":"UMIB\u2014Unit for Multidisciplinary Research in Biomedicine, 4050-346 Porto, Portugal"},{"name":"ICBAS\u2014School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21037\/tlcr.2020.01.12","article-title":"KEYNOTE-407: Changing the Way We Treat Stage IV Squamous Non-Small Cell Lung Cancer","volume":"9","author":"Pacheco","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.21037\/jtd-22-1192","article-title":"Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer: A Narrative Review on Mechanisms, Efficacy and Safety","volume":"14","author":"Shao","year":"2022","journal-title":"J. Thorac. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1026964","DOI":"10.3389\/fimmu.2022.1026964","article-title":"Association between Immune-Mediated Adverse Events and Efficacy in Metastatic Non-Small-Cell Lung Cancer Patients Treated with Durvalumab and Tremelimumab","volume":"13","author":"Dey","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like Depigmentation in Patients with Stage III\u2013IV Melanoma Receiving Immunotherapy and Its Association with Survival: A Systematic Review and Meta-Analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo with Tumor Response in Patients with Metastatic Melanoma Treated with Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under Anti-Programmed Cell Death-1 Therapy Is Associated with Increased Survival in Melanoma Patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and Prognosis of Individuals Receiving Programmed Cell Death 1 Inhibitor with and without Immunologic Cutaneous Adverse Events","volume":"82","author":"Chan","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab Cutaneous Adverse Events and Their Association with Disease Progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between Vitiligo Occurrence and Clinical Benefit in Advanced Melanoma Patients Treated with Nivolumab: A Multi-Institutional Retrospective Study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1046\/j.0022-202x.2001.01605.x","article-title":"Direct Evidence to Support the Role of Antigen-Specific CD8+ T Cells in Melanoma-Associated Vitiligo","volume":"117","author":"Avril","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1901278","DOI":"10.1002\/advs.201901278","article-title":"Granulocytic Myeloid-Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1523-1747.2003.12413.x","article-title":"Cytotoxic T Lymphocyte Reactivity to Gp100, MelanA\/MART-1, and Tyrosinase, in HLA-A2-Positive Vitiligo Patients","volume":"121","author":"Shear","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune Checkpoint Inhibitor\u2014Related Dermatologic Adverse Events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.21781","article-title":"Clinical Associations and Classification of Immune Checkpoint Inhibitor-Induced Cutaneous Toxicities: A Multicentre Study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.21037\/tlcr-20-386","article-title":"Vitiligo-like Depigmentation after Pembrolizumab Treatment in Patients with Non-Small Cell Lung Cancer: A Case Report","volume":"9","author":"Yun","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jdcr.2018.08.009","article-title":"Vitiligo in a Patient Undergoing Nivolumab Treatment for Non\u2013Small Cell Lung Cancer","volume":"4","author":"Kosche","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E481","DOI":"10.21037\/jtd.2018.05.104","article-title":"Nivolumab Induced Vitiligo-like Lesions in a Patient with Metastatic Squamous Cell Carcinoma of the Lung","volume":"10","author":"Nishino","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/bcp.14663","article-title":"Pembrolizumab-Induced Vitiligo in a Patient with Lung Adenocarcinoma: A Case Report","volume":"87","author":"Bulat","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ced.13867","article-title":"Vitiligo-like Depigmentation in Oncology Patients Treated with Immunotherapies for Nonmelanoma Metastatic Cancers","volume":"44","author":"Liu","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41571-021-00508-x","article-title":"Beneficial Autoimmunity Improves Cancer Prognosis","volume":"18","author":"Zitvogel","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.18.01223","article-title":"Markedly Reduced Risk of Internal Malignancies in Patients with Vitiligo: A Nationwide Population-Based Cohort Study","volume":"37","author":"Bae","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly Reduced Incidence of Melanoma and Nonmelanoma Skin Cancer in a Nonconcurrent Cohort of 10,040 Patients with Vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00432-020-03245-3","article-title":"Cancer Risks in Patients with Vitiligo: A Mendelian Randomization Study","volume":"146","author":"Wen","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of Cutaneous Immune-Related Adverse Events with Increased Survival in Patients Treated with Anti\u2013Programmed Cell Death 1 and Anti\u2013Programmed Cell Death Ligand 1 Therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: An Update on Pathophysiology and Treatment Options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients","volume":"129","author":"Luiten","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced Skin Homing by Functional Treg in Vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","article-title":"Prognostic Significance of Cutaneous Adverse Events Associated with Pembrolizumab Therapy","volume":"1","author":"Lo","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hermann, N., Maul, L.V., Ameri, M., Traidl, S., Ziadlou, R., Papageorgiou, K., Kolm, I., Levesque, M., Maul, J.T., and Br\u00fcggen, M.C. (2022). Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study. Cancers, 14.","DOI":"10.3390\/cancers14194576"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jdin.2021.09.002","article-title":"Analysis of Tumor Response and Clinical Factors Associated with Vitiligo in Patients Receiving Anti-Programmed Cell Death-1 Therapies for Melanoma: A Cross-Sectional Study","volume":"5","author":"Dousset","year":"2021","journal-title":"JAAD Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40264-019-00875-6","article-title":"Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study","volume":"43","author":"Babai","year":"2020","journal-title":"Drug Saf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1099108","DOI":"10.3389\/fonc.2022.1099108","article-title":"Case Report: Immune Checkpoint Inhibitor-Related Vitiligo-like Depigmentation in Non-Melanoma Advanced Cancer: A Report of Three Cases and a Pooled Analysis of Individual Patient Data","volume":"12","author":"Rao","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-Related Adverse Events and Survival in Solid Tumors Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Rom\u00e3o, R., Mendes, A.S., Ranchor, R., Ramos, M.J., Coelho, J., Pichel, R.C., Azevedo, S.X., Fidalgo, P., and Ara\u00fajo, A. (2023). Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients\u2019 Survival: Single Center Experience and Literature Review. Cancers, 15.","DOI":"10.3390\/cancers15030888"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., and Zhang, F. (2020). Are Immune-Related Adverse Events Associated with the Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer? A Systematic Review and Meta-Analysis. BMC Med., 18.","DOI":"10.1186\/s12916-020-01549-2"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3319","article-title":"Clinical and Pathological Relevance of Drug-Induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF\/MEK Inhibitors","volume":"100","author":"Ramondetta","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eaam6346","DOI":"10.1126\/sciimmunol.aam6346","article-title":"Resident Memory T Cells in the Skin Mediate Durable Immunity to Melanoma","volume":"2","author":"Malik","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1073\/pnas.96.6.2982","article-title":"Vaccination with a Recombinant Vaccinia Virus Encoding a \u201cSelf\u201d Antigen Induces Autoimmune Vitiligo and Tumor Cell Destruction in Mice: Requirement for CD4+ T Lymphocytes","volume":"96","author":"Overwijk","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1755-148X.2010.00703.x","article-title":"First Histopathological and Immunophenotypic Analysis of Early Dynamic Events in a Patient with Segmental Vitiligo Associated with Halo Nevi","volume":"23","author":"Mollet","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1900027","article-title":"The Role of Memory CD8+ T Cells in Vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-\u03b3 for Autoreactive CD8+ T-Cell Accumulation in the Skin","volume":"132","author":"Harris","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1122430","DOI":"10.3389\/fimmu.2023.1122430","article-title":"Immune-Related Adverse Events in Checkpoint Blockade: Observations from Human Tissue and Therapeutic Considerations","volume":"14","author":"Williams","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like Lesions Occurring in Patients Receiving Anti-Programmed Cell Death-1 Therapies Are Clinically and Biologically Distinct from Vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1197630","DOI":"10.3389\/fimmu.2023.1197630","article-title":"Insight into Immune Profile Associated with Vitiligo Onset and Anti-Tumoral Response in Melanoma Patients Receiving Anti-PD-1 Immunotherapy","volume":"14","author":"Carbone","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of Nivolumab-Associated Skin Reactions in Patients with Metastatic Non-Small Cell Lung Cancer","volume":"5","author":"Diem","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00403-023-02577-7","article-title":"Immune Checkpoint Inhibitor-Induced Vitiligo in Cancer Patients: Characterization and Management","volume":"315","author":"Lo","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100200","DOI":"10.1016\/j.ctarc.2020.100200","article-title":"KRAS Mutation as a Prognostic Factor and Predictive Factor in Advanced\/Metastatic Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis","volume":"24","author":"Goulding","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17588359211006950","DOI":"10.1177\/17588359211006950","article-title":"KRAS\/LKB1 and KRAS\/TP53 Co-Mutations Create Divergent Immune Signatures in Lung Adenocarcinomas","volume":"13","author":"Gu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Casagrande, G.M.S., Silva, M.d.O., Reis, R.M., and Leal, L.F. (2023). Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032505"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/oncolo\/oyac035","article-title":"Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers with Lung Adenocarcinoma","volume":"27","author":"Mack","year":"2022","journal-title":"Oncologist"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results from the Randomized Phase 3 IMpower132 Trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB\u2013IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for First-Line Treatment of PD-L1\u2013Selected Patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non\u2013Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with PD-L1 of at Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau-Faller, M., and Mascaux, C. (2023). Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087577"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Huang, Y., Chau, Y.F., Bai, H., Wu, X., and Duan, J. (2023). Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914521"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12957-023-03215-2","article-title":"Prognostic Significance of Blood-Based PD-L1 Analysis in Patients with Non-Small Cell Lung Cancer Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis","volume":"21","author":"Cui","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1158\/1078-0432.CCR-22-0992","article-title":"PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC","volume":"28","author":"Hummelink","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101788","DOI":"10.1016\/j.tranon.2023.101788","article-title":"Tumor Mutation Burden in the Prognosis and Response of Lung Cancer Patients to Immune-Checkpoint Inhibition Therapies","volume":"38","author":"Vryza","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1111\/1759-7714.15098","article-title":"Prognostic and Predictive Impact of Molecular Tumor Burden Index in Non-Small Cell Lung Cancer Patients","volume":"14","author":"Yang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","article-title":"TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti\u2013PD-1 in Lung Adenocarcinoma","volume":"24","author":"Biton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune Checkpoint Inhibitors for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations: Results from the IMMUNOTARGET Registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1356145","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR Mutation Correlates with Uninflamed Phenotype and Weak Immunogenicity, Causing Impaired Response to PD-1 Blockade in Non-Small Cell Lung Cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21037\/tlcr.2019.10.22","article-title":"Targeting BRAF Mutations in Non-Small Cell Lung Cancer","volume":"8","author":"Andelkovic","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e000706","DOI":"10.1136\/esmoopen-2020-000706","article-title":"STK11 and KEAP1 Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma Cohort","volume":"5","author":"Doshi","year":"2020","journal-title":"ESMO Open"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ying, K., Zou, L., Wang, D., Wang, R., and Qian, J. (2023). Co-Mutation of TP53 and TTN Is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma. Comb. Chem. High Throughput Screen., 26.","DOI":"10.2174\/0113862073246841230922052004"},{"key":"ref_79","first-page":"101818","article-title":"Gene Expression Profiles (GEPs) of Immuno-Oncologic Pathways as Predictors of Response to Checkpoint Inhibitors in Advanced NSCLC","volume":"39","author":"Leal","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Mouritzen, M.T., Ladekarl, M., Hager, H., Mattesen, T.B., Lippert, J.B., Frank, M.S., N\u00f8hr, A.K., Egendal, I.B., and Carus, A. (2023). Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancers, 15.","DOI":"10.3390\/cancers15184480"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1111\/cas.15964","article-title":"Peripheral Blood Inflammatory Biomarkers Dynamics Reflect Treatment Response and Predict Prognosis in Non-Small Cell Lung Cancer Patients with Neoadjuvant Immunotherapy","volume":"114","author":"Huai","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_82","first-page":"605","article-title":"Peripheral Blood Laboratory Test Results Combined with TCF1+CD8+ T Lymphocytes Ratio to Predict the Response and Prognosis of Immunotherapy to Advanced Lung Cancer","volume":"26","author":"Luo","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/83\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:14Z","timestamp":1760104934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["curroncol31020083"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31020083","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}